Acelyrin, Inc. (SLRN)
NASDAQ: SLRN · Real-Time Price · USD
2.600
-0.040 (-1.52%)
At close: Mar 28, 2025, 4:00 PM
2.355
-0.245 (-9.42%)
Pre-market: Mar 31, 2025, 8:00 AM EDT
Acelyrin Employees
Acelyrin had 83 employees as of December 31, 2024. The number of employees decreased by 52 or -38.52% compared to the previous year.
Employees
83
Change (1Y)
-52
Growth (1Y)
-38.52%
Revenue / Employee
n/a
Profits / Employee
-$2,990,675
Market Cap
261.85M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 83 | -52 | -38.52% |
| Dec 31, 2023 | 135 | 88 | 187.23% |
| Dec 31, 2022 | 47 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLRN News
- 18 days ago - ACELYRIN Adopts Limited-Duration Stockholder Rights Plan - GlobeNewsWire
- 26 days ago - ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger - GlobeNewsWire
- 26 days ago - ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger - GlobeNewsWire
- 5 weeks ago - ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences - GlobeNewsWire
- 6 weeks ago - ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN - Business Wire
- 7 weeks ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC. - PRNewsWire
- 2 months ago - Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 2 months ago - ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease - GlobeNewsWire